Blood test may predict radiation therapy response
Part of Cancer clinical trials.
This study looks at a simple blood test to help predict how well your tumor will respond to radiation therapy. By measuring a protein called CHI3L1 in your blood before and during treatment, the study aims to help doctors personalize your care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with one of these cancers: nasopharyngeal, head and neck, lung, breast, stomach, colorectal, brain (glioma), esophageal, liver, bile duct (cholangiocarcinoma), cervical, prostate, or bladder cancer.
- You are physically able to take care of yourself and are fully active, or you can do light work around the house or office.
- You do not have serious, unstable health conditions like unstable heart disease, poorly controlled diabetes, active hepatitis, kidney disease, or psychiatric disorders.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects blood and urine samples from patients receiving radiation therapy to understand how the body responds to treatment. It may help researchers improve radiation therapy in the future.
This study looks at a blood test (biomarker) to see how well people with hepatitis B-related liver cancer respond to radiation therapy and what their long-term outlook may be. It aims to find better ways to predict treatment outcomes.
This study looks at tumor tissue and/or blood “biomarkers” to help predict whether a solid tumor will respond well to radiation therapy. It may help doctors choose more effective treatments in the future, and it may guide your care during radiotherapy if you qualify.
This trial tests whether a blood test (ctDNA) can help predict how well a combination of chemotherapy and immunotherapy (and sometimes radiation) works before surgery for non-small cell lung cancer. It aims to see if the blood test can detect small amounts of remaining cancer to guide further treatment.
This study looks for “biomarkers,” or measurable signs (often from blood or samples), that may show which cancers respond better to radiation therapy. It may help doctors choose radiation treatment more precisely, especially for people who had significant side effects before.
This study looks at blood markers—tiny DNA from the blood (cfDNA) and minimal residual disease (MRD)—to better predict outcomes after standard chemoradiotherapy for locally advanced cervical cancer. It may help doctors identify who is more likely to do well and who may need closer follow-up or additional treatment planning.
Hear when a new Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.